Concord Biotech Ltd

Concord Biotech Ltd share price ticked higher by 0.23% to Rs 1333.2. The Company's net profit plunged by 34.78% to Rs 57.7 crore, while revenue from operations nosedived 21.03% to Rs 257.49 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 6%. It has marginally improved by 2.79% over last one week and spiked sharply by 15.59% in last one month while the market capitalization of Concord Biotech Ltd has gained 13.75% and 24.57% in the same period respectively. Profit before tax (PBT) of Concord Biotech Ltd stood at Rs 78.34 crore in Q2 FY26, jumping 33.39% year-on-year, and plunging by 31.33% quarter-on-quarter. EBITDA came in at Rs 70 crore, rallying 45.75% YoY and nosediving by 32.59% sequentially. Total expenses fell by 14.92% to Rs 193.21 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 69.85 crore, slightly declining by 0.98% YoY, while employee benefits expense was at Rs 43.64 crore, dropping 8.65% YoY. For the TTM ended FY26, revenue from operations fell 12.10% to Rs 1054.89 crore, while net profit tanked by 30.25% to Rs 259.23 crore, compared to previous TTM. EBITDA jumped by 48097% to Rs 315.04 crore, and PBT collapsed by 30.31% to Rs 344.65 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 266.88 crore in FY26, as against Rs 244.52 crore in FY25. Concord Biotech Ltd crashed 26.39% in last one year, underperforming the benchmark BSE Sensex which has slipped by 4.36% during the same period.

Concord Biotech will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Concord Biotech announced that the 41th Annual General Meeting(AGM) of the company will be held on 31 July 2026.

Concord Biotech has fixed 24 July 2026 as record date for payment of final dividend for FY 2026.

Concord Biotech announced the successful completion of inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit-II formulation facility. The inspection took place from 18 June 2026 to 24 June 2026, and was concluded successfully.

The inspection took place from 18 June 2026 to 24 June 2026. The successful completion of PPB and NDA inspection marks a significant milestone in Concord Biotech's global growth journey. 'This achievement reinforces our commitment to the highest standards of quality and regulatory excellence while strengthening our global manufacturing and regulatory footprint,' the company said in a statement. Concord Biotech is an R&D-driven biopharma company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation & semi-synthetic processes and finished formulations. It has a presence in more than 70 countries worldwide. The company's consolidated net profit declined 36.75% to Rs 88.79 crore on a 24.15% drop in revenue from operations to Rs 326.07 crore in Q4 FY26 over Q4 FY25. The scrip rose 0.63% to currently trade at Rs 1296.80 on the BSE. Powered by Capital Market - Live

Concord Biotech announced the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at the company's API manufacturing facility in Limbasi. The inspection took place from 08 June to 12 June 2026, and was concluded successfully.

The inspection was carried out between 8 June and 12 June 2026 and concluded successfully, the company said in a regulatory filing. The company said, The successful completion of the ANVISA inspection marks a significant milestone in Concord Biotech's global growth journey. This achievement reinforces our commitment to the highest standards of quality and regulatory excellence while strengthening our global manufacturing and regulatory footprint. It also advances our international expansion strategy by enhancing access to one of the world's largest pharmaceutical markets and broadening the reach of our high-quality APIs across key geographies. Concord Biotech is an R&D-driven biopharma company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation & semi-synthetic processes and finished formulations. It has a presence in more than 70 countries worldwide. The company's consolidated net profit declined 36.75% to Rs 88.79 crore on a 24.15% drop in revenue from operations to Rs 326.07 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live

Concord Biotech has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg. Tofacitinib tablets are indicated for the treatment of adult patients with Moderately to severely active rheumatoid arthritis (RA), Active psoriatic arthritis (PsA), Active ankylosing spondylitis (AS), Moderately to severely active ulcerative colitis (UC), Active PsA, Active polyarticular course juvenile idiopathic arthritis (pcJIA). According to market estimates, the U.S. market for Tofacitinib Tablets both strengths put together is approximately US$ 500 million. The approval positions the Company to capitalize on these attractive market opportunities, enhance its product offerings, and support its long-term growth strategy across the U.S. and international markets.

Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular-course juvenile idiopathic arthritis. According to market estimates, the US market size for Tofacitinib tablets across both strengths is approximately $500 million. The approval is expected to enable the company to tap this market opportunity, expand its product portfolio, and support its long-term growth strategy in the US and other international markets. Concord Biotech is an R&D-driven biopharma company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation & semi-synthetic processes and finished formulations. It has a presence in more than 70 countries worldwide. The company's consolidated net profit declined 36.75% to Rs 88.79 crore on a 24.15% drop in revenue from operations to Rs 326.07 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live